<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216265</url>
  </required_header>
  <id_info>
    <org_study_id>207451</org_study_id>
    <nct_id>NCT03216265</nct_id>
  </id_info>
  <brief_title>A Proof of Concept Clinical Study to Investigate the Effects of an Experimental Cosmetic Moisturiser on the Barrier Function of Human Skin on the Face and Forearm</brief_title>
  <official_title>A Proof of Concept (POC) Clinical Study to Investigate the Effects of a Developmental Cosmetic Moisturising Cream on the Barrier Function of Human Skin on the Face and Forearm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this POC clinical study is to investigate the impact of the test product
      (Developmental Cosmetic Moisturising Cream) on skin barrier function and skin moisturisation
      on the forearm and face after 4 weeks of twice daily application compared to no treatment in
      participants with dry sensitive skin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Areas on the volar forearm and each side of the face, will be selected for measurements of
      transepidermal water loss (TEWL) and corneometry to be conducted . A physical challenge and a
      regression period of 5 days is also included to evaluate skin barrier function and
      moisturisation.

      A regression period of 5 days (Days 30, 31, 32, 33 and 34) of no study product use following
      the 4 week treatment phase is also included to evaluate skin barrier function and
      moisturisation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2017</start_date>
  <completion_date type="Actual">April 24, 2017</completion_date>
  <primary_completion_date type="Actual">April 19, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in transepidermal water loss (TEWL) measurements on Day 29 of test product treated versus (vs.) untreated sites on the forearm</measure>
    <time_frame>At Baseline and Day 29</time_frame>
    <description>TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe will be held in place on the skin for one measurement, for approximately 40 seconds (sec), to ensure that a stable value has been established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 seconds are averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in transepidermal water loss (TEWL) measurements on Day 29 of test product treated vs. untreated sites on the face</measure>
    <time_frame>At Baseline and Day 29</time_frame>
    <description>TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe will be held in place on the skin for one measurement, for approximately 40 seconds (sec), to ensure that a stable value has been established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 seconds are averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in corneometry on the forearm and face, test product treated vs. untreated sites</measure>
    <time_frame>At Baseline, Day 1 (30 minutes and 6 hours post study product application), Day 2, 15, and 29</time_frame>
    <description>Corneometry will be used to measure moisture content of stratum corneum using corneometer. The measuring principle is based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field is built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content. The Corneometer measurements will be taken 5 times in total and then an average reading will be calculated for each site and time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in transepidermal water loss (TEWL) on the forearm and face, test product treated vs. untreated sites at Day 1, 2 and 15</measure>
    <time_frame>At Baseline, Day 1, Day 2, and 15</time_frame>
    <description>TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe will be held in place on the skin for one measurement, for approximately 40 seconds (sec), to ensure that a stable value has been established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 seconds are averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardised area under curve (AUC) of change from baseline in corneometry over treatment period</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Standardised AUC will be calculated for each subject for change from baseline in corneometry on forearms and face over the treatment period; i.e. through Day 29. Corneometry will be performed as given in the above secondary outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardised area under curve (AUC) of change from baseline in transepidermal water loss (TEWL) over treatment period</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Standardised AUC will be calculated for each subject for change from baseline in TEWL on the forearms and face over the treatment period; i.e. through Day 29. TEWL will be calculated as given in the primary outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-challenge in transepidermal water loss (TEWL) measurements of D-Squame discs following 4, 8 and 12 adhesive discs removal from skin of both test product treated and untreated sites on the forearm on Day 29</measure>
    <time_frame>On Day 29 (including Pre-challenge)</time_frame>
    <description>A series of D-Squame discs will be gently smoothed over the designated D-Squame Areas by applying a uniform pressure for 5 sec with a stamp to ensure consistent adhesion to the skin. Each disc will be pulled off the skin with one fluent and decisive movement. There will be a maximum of 12 D-Squame discs (in groups of 4) removed from each forearm repeatedly. TEWL will be measured (as per primary outcome) pre challenge and after 4, 8 and 12 discs have been removed from the forearms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-challenge in transepidermal water loss (TEWL) measurements of D-Squame discs following 3, 6 and 9 adhesive discs removal from skin of both test product treated and untreated sites on the face on Day 29</measure>
    <time_frame>On Day 29 (including Pre-challenge)</time_frame>
    <description>A series of D-Squame discs will be gently smoothed over the designated D-Squame Areas by applying a uniform pressure for 5 sec with a stamp to ensure consistent adhesion to the skin. Each disc will be pulled off the skin with one fluent and decisive movement. There will be a maximum of 9 D-Squame discs (in groups of 3) removed from the face repeatedly. TEWL will be measured (as per primary outcome) pre challenge and after 3, 6 and 9 discs have been removed from the face.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein analysis (SquameScan) of D-Squame discs following removal of 4, 8 and 12 adhesive discs from skin of both test product treated and untreated sites on the forearm on Day 29</measure>
    <time_frame>On Day 29</time_frame>
    <description>The protein content of each D-Squame disc will be analysed using a SquameScan. SquameScan is the instrument used to indirectly measure the protein content extracted from the skin by D-squame tape strips. Determination is performed by measuring the optical absorption of the strip at about 850 nanometres (nm) (infrared light). The value displayed in % is proportionally related to the protein content. The protein content will be analysed for each of the discs obtained the D-Squame stripping on the forearms and reported to 2 decimal places.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein analysis of D-Squame discs following removal of 3, 6 and 9 adhesive discs from skin of both test product treated and untreated sites on the face on Day 29</measure>
    <time_frame>On Day 29</time_frame>
    <description>The protein content of each D-Squame disc will be analysed using a SquameScan. SquameScan is the instrument used to indirectly measure the protein content extracted from the skin by D-squame tape strips. Determination is performed by measuring the optical absorption of the strip at about 850 nm (infrared light). The value displayed in % is proportionally related to the protein content. The protein content will be analysed for each of the discs obtained the D-Squame stripping on the face and reported to 2 decimal places.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline and from Day 29 in transepidermal water loss (TEWL) measurements on Days 30, 31, 32, 33 and 34 in test product treated vs. untreated sites on the forearm and face</measure>
    <time_frame>At Baseline, Day 29, 30, 31, 32, 33,and 34</time_frame>
    <description>TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe will be held in place on the skin for one measurement, for approximately 40 seconds (sec), to ensure that a stable value has been established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 seconds are averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardised AUC calculated using change from baseline and from Day 29 in transepidermal water loss (TEWL) over regression period (Days 30, 31, 32, 33 and 34) of forearm and face</measure>
    <time_frame>At baseline, Day 29, 30, 31, 32, 33 and 34</time_frame>
    <description>Standardised AUC will be calculated for each subject for change from baseline and Day 29 in TEWL over the Regression period; i.e. through Day 34.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline and from Day 29 in Corneometry measurements on Days 30, 31, 32, 33 and 34 in test product treated site vs untreated site on the forearm and face</measure>
    <time_frame>At baseline, Day 29, 30, 31, 32, 33, and 34</time_frame>
    <description>Corneometry will be used to measure moisture content of stratum corneum using corneometer. The measuring principle is based on changes in the capacitance of the measuring head, functioning as a condensator. Between the conductors of the probe an electrical field is built which allows the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content. The Corneometer measurements will be taken 5 times in total and then an average reading will be calculated for each site and time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardised AUC calculated using change from baseline and from Day 29 in corneometry over regression period (Days 30, 31, 32, 33 and 34) on the forearm and face</measure>
    <time_frame>At baseline, Day 29, 30, 31, 32, 33, and 34</time_frame>
    <description>Standardised AUC will be calculated for each subject for change from baseline and Day 29 in TEWL over the Regression period; i.e. through Day 34.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in transepidermal water loss (TEWL) measurements on Day 29 of positive control treated vs. untreated sites on the forearm</measure>
    <time_frame>At baseline and Day 29</time_frame>
    <description>TEWL measuring principle is based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe will be held in place on the skin for one measurement, for approximately 40 seconds (sec), to ensure that a stable value has been established. The first part of the measurement belongs to the equilibration phase. The values of the last 10 seconds are averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Up to Day 34</time_frame>
    <description>Local tolerance will be measured by recording frequency and severity of AEs.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Skin Care</condition>
  <arm_group>
    <arm_group_label>Test product/ No treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test product/positive control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants randomized to this arm will apply Test and positive product at allocated sites.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive control /no treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Test product (Moisturising cream)</intervention_name>
    <description>Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).</description>
    <arm_group_label>Test product/positive control</arm_group_label>
    <arm_group_label>Test product/ No treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Positive control (Commercial market place moisturising cream)</intervention_name>
    <description>Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).</description>
    <arm_group_label>Test product/positive control</arm_group_label>
    <arm_group_label>Positive control /no treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment</intervention_name>
    <description>No treatment.</description>
    <arm_group_label>Positive control /no treatment</arm_group_label>
    <arm_group_label>Test product/ No treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Demonstrates understanding of the study procedures, restrictions and willingness to
             participate as evidenced by voluntary written informed consent and has received a
             signed and dated copy of the informed consent form.

          -  Good general and mental health with, in the opinion of the investigator or medically
             qualified designee no clinically significant and relevant abnormalities in medical
             history or upon physical examination.

          -  Self-reported dry, sensitive skin on the face and body.

          -  Agreement to comply with the procedures and requirements of the study and to attend
             the scheduled assessment visits.

          -  Trained examiner visual grading assessment score (including subject self-assessment of
             tightness) of overall dryness â‰¥ 3 with a score of at least 1 in the roughness
             parameter and 4 (for any individual parameter) on each of the forearms and each side
             of the face at the Screening visit (Visit 1) and Baseline visit (Visit 2).

          -  In addition, there will be no greater than 0.5 point difference between trained
             examiner visual grading scores of each volar forearm and each side of the face at the
             Screening and Baseline visits.

          -  Fitzpatrick skin type I-IV

        Exclusion Criteria:

          -  Women who are known to be pregnant or who are intending to become pregnant over the
             duration of the study.

          -  Women who are breast-feeding.

          -  Any history of significant dermatological diseases or conditions or medical conditions
             known to alter skin appearance or physiologic response (e.g. diabetes) which could, in
             the opinion of the Investigator, preclude topical application of the investigational
             products and/or interfere with the evaluations.

          -  Presence of open sores, pimples, or cysts at the application site.

          -  Active dermatosis (local or disseminated) that might interfere with the results of the
             study.

          -  Considered immune compromised.

          -  Currently using any medication which in the opinion of the investigator, may affect
             the evaluation of the study product, or place the subject at undue risk.

          -  Use of the following topical or systemic medications: immunosuppressants,
             antihistamines, non-hormonal anti-inflammatory drugs, and corticosteroids up to 2
             weeks before screening visit.

          -  Intention of using any oral or topical steroids.

          -  Regular use of inhaled steroids (occasional use is permitted).

          -  Regular use of topical anti-itch medications (occasional use permitted; the product
             should be applied with an applicator but not to the proposed application areas.

          -  Use of any topical drug or medication in the proposed application areas.

          -  Intention of being vaccinated during the study period or has been vaccinated within 3
             weeks of the screening visit.

          -  Currently receiving allergy injections, or received an allergy injection within 7 days
             prior to Visit 1, or expects to begin injections during study participation.

          -  Previous history of atopy, allergic reactions, irritation or intense discomfort
             feelings to topical-use products, cosmetics or medication.

          -  Known or suspected intolerance or hypersensitivity to any of the study materials (or
             closely related compounds) or any of their stated ingredients.

          -  Participation in another clinical study (including cosmetic studies) or receipt of an
             investigational drug within 14 days of the screening visit.

          -  Previous participation in this study.

          -  Recent history (within the last 5 years) of alcohol or other substance abuse.

          -  Smoker (including e-cigarettes)

          -  Moles, tattoos, scars, hairs, etc. at the test areas if it is likely that they could
             affect the assessments.

          -  Subject has visible sunburn on the test sites.

          -  Use of self-tanning products on the test areas (face and arms) within 2 weeks prior to
             the screening visit.

          -  Any individual parameter score 4 on any test areas of the face or either of the
             forearms as assessed by a trained examiner.

          -  Any Subject who, in the judgment of the Investigator, should not participate in the
             study.

          -  An employee of the sponsor or the study site or members of their immediate family.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schenefeld</city>
        <state>Schleswig-Holstein</state>
        <zip>22869</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>April 5, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

